LubioScience, Switzerland’s largest R&D reagent platform, has teamed up with Integrated DNA Technologies (IDT) to launch Rapid Genes, a revolutionary product designed to streamline high-throughput workflows. The genes are shipped in as little as five business days, offering speed and precision that will significantly benefit researchers and biotech companies.
The Rapid Genes provides unmatched accuracy, with each gene verified by Next-Generation Sequencing (NGS) to ensure 100% sequence accuracy. This guarantees that genetic constructs are error-free, a critical requirement for fields like drug development, gene therapies, and vaccine research. The fast turnaround time of 5-8 business days allows researchers to quickly synthesize and scale their projects, reducing typical delays in gene synthesis.
Designed to support a wide range of applications, Rapid Genes are ideal for high-throughput workflows in cloning as well as mammalian and bacterial expression systems. Available in multiple plate formats and compatible with different vectors, the product offers great flexibility to meet the demands of high-throughput drug screening and genetic research, particularly for the growing biotech sector in Switzerland.
"We are excited to partner with IDT to bring Rapid Genes to the Swiss biotech community. This innovative product will help accelerate research and development efforts by providing high-quality genes in record time,” said Dr. Muriel Revol, Managing Director of LubioScience.
In addition, LubioScience and IDT provide a custom vector onboarding service, enabling full integration of proprietary vectors into the Rapid Genes platform. This unique service ensures full intellectual property protection throughout the process.